Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekAJMC ↗
SENTRY Trial Shows Survival, Spleen Benefits in Myelofibrosis: Claire Harrison, MD…
The WeekSTAT News ↗
The director-general of the World Health Organization is profoundly worried about the Ebola outbreak in the DR…
The WeekFiercePharma ↗
J&J's MonumenTAL-3 phase 3 study of bispecific antibody Talvey and Darzalex Faspro in patients with earlie…
The WeekFierceBiotech ↗
Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings …
The WeekBriefing
Prometheus secured $12 billion to build its “artificial engineers,” part of a week of biotech activity spannin…
The WeekAJMC ↗
Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD…
The WeekSTAT News ↗
Opinion: 'I'm pretty much all in': An interview with a woman starting medical residency at almost 73
"There are some physicians that work to 100": Dawn Zuidgeest-Craft on becoming a medical doctor in her 70s.…
The WeekSTAT News ↗
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmace…
The WeekBioPharma Dive ↗
In a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company i…
The WeekSTAT News ↗
The nonprofit Blood Cancer United is buying the remaining supplies of a discontinued investigational cancer dr…
The WeekPharmaVoice ↗
As it prepares to compete in the KRAS arena, the Japanese pharma has retooled its approach to clinical develop…
The WeekSTAT News ↗
Kennedy's "publicly" "available" "calendar," drinking during pregnancy, and more health news from Morning Roun…
The WeekFiercePharma ↗
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevi…
The WeekFierceBiotech ↗
Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, set…
The WeekBriefing
Johnson & Johnson reported pivotal trial success for Imaavy in warm autoimmune hemolytic anemia, a rare diseas…
The WeekDrug Channels ↗
This week, we're rerunning some popular posts while we prepare for today's live video webinar: 340B in 2026: M…
The WeekDrug Channels ↗
This week, we're rerunning some popular posts while we prepare for today's live video webinar: 340B in 2026: M…
The WeekDrug Channels ↗
This week, we're rerunning some popular posts while we prepare for today's live video webinar: 340B in 2026: M…
The WeekSTAT News ↗
Hospital execs agree that affordability is a major issue. What to do about it is less clear.…
The WeekAJMC ↗
How Healthy Gut Microbiota Can Give CAR T-Cell Recipients a Leg Up…
The WeekBioPharma Dive ↗
The developer of a leading PD-1/VEGF cancer drug cited "market conditions" for the cancellation. Its shares ha…
The WeekBioPharma Dive ↗
A strategic review determined that the development environment had "notably changed," leading Sensorion to end…
The WeekBioPharma Dive ↗
The data showed that del-brax, an "antisense oligonucleotide conjugate" being tested against a muscle-wasting …
The WeekBioPharma Dive ↗
New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed dat…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.